Gilead Sciences Inc (GILD):企業の財務・戦略的SWOT分析

◆英語タイトル:Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH5315FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:69
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Gilead Sciences Inc (GILD) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

Gilead Sciences Inc Key Recent Developments

Mar 19,2021: Gilead and Novo Nordisk expand NASH collaboration
Mar 17,2021: Gilead and Merck partner to co-develop long-acting HIV treatments
Mar 16,2021: COTA and Kite collaborate to expand the use of Real-World Data to drive faster, effective treatments for cancers
Mar 15,2021: Gilead and Merck announce agreement to jointly develop and commercialize long-acting, Investigational treatment combinations of Lenacapavir and Islatravir in HIV
Mar 04,2021: Gilead Sciences Completes Acquisition of MYR GmbH

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Gilead Sciences Inc – Key Facts
Gilead Sciences Inc – Key Employees
Gilead Sciences Inc – Key Employee Biographies
Gilead Sciences Inc – Major Products and Services
Gilead Sciences Inc – History
Gilead Sciences Inc – Company Statement
Gilead Sciences Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Gilead Sciences Inc – Business Description
Geographical Segment: Europe
Performance
Geographical Segment: Other International
Performance
Geographical Segment: United States
Performance
R&D Overview
Gilead Sciences Inc – Corporate Strategy
Gilead Sciences Inc – SWOT Analysis
SWOT Analysis – Overview
Gilead Sciences Inc – Strengths
Gilead Sciences Inc – Weaknesses
Gilead Sciences Inc – Opportunities
Gilead Sciences Inc – Threats
Gilead Sciences Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Gilead Sciences Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 19, 2021: Gilead and Novo Nordisk expand NASH collaboration
Mar 17, 2021: Gilead and Merck partner to co-develop long-acting HIV treatments
Mar 16, 2021: COTA and Kite collaborate to expand the use of Real-World Data to drive faster, effective treatments for cancers
Mar 15, 2021: Gilead and Merck announce agreement to jointly develop and commercialize long-acting, Investigational treatment combinations of Lenacapavir and Islatravir in HIV
Mar 02, 2021: Gilead to present new data at CROI 2021 demonstrating the company’s commitment to addressing urgent global health needs
Feb 16, 2021: Gilead Sciences and Wake Forest University School of Divinity partner to address HIV epidemic through faith-based programming and community outreach
Feb 09, 2021: Gilead announces plans for new location in North Carolina’s research Triangle region dedicated to business services
Feb 08, 2021: Kite Appoints Frank Neumann as Worldwide Head of Clinical Development
Feb 04, 2021: Gilead Sciences announces fourth quarter and full year 2020 financial results
Feb 02, 2021: Gilead and the Human Rights Campaign will work together to combat HIV epidemic and promote transgender justice
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Gilead Sciences Inc, Key Facts
Gilead Sciences Inc, Key Employees
Gilead Sciences Inc, Key Employee Biographies
Gilead Sciences Inc, Major Products and Services
Gilead Sciences Inc, History
Gilead Sciences Inc, Other Locations
Gilead Sciences Inc, Subsidiaries
Gilead Sciences Inc, Joint Venture
Gilead Sciences Inc, Key Competitors
Gilead Sciences Inc, Ratios based on current share price
Gilead Sciences Inc, Annual Ratios
Gilead Sciences Inc, Annual Ratios (Cont...1)
Gilead Sciences Inc, Annual Ratios (Cont...2)
Gilead Sciences Inc, Interim Ratios
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Gilead Sciences Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Gilead Sciences Inc (GILD):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Black & Veatch Holding Company:企業の戦略・SWOT・財務分析
    Black & Veatch Holding Company - Strategy, SWOT and Corporate Finance Report Summary Black & Veatch Holding Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Shanghai Pharmaceutical Co Ltd (601607):企業の財務・戦略的SWOT分析
    Shanghai Pharmaceutical Co Ltd (601607) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Tottenham Hotspur Ltd:企業の戦略的SWOT分析
    Tottenham Hotspur Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • EpiVax Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary EpiVax Inc (EpiVax) develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear sequences of amino acids which ac …
  • USV Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary USV Pvt Ltd (USV) is a healthcare company that offers pharmaceutical products. The company’s products include active pharmaceutical ingredients, biosimilars, injectables, ophthalmics, peptides and solid orals. Its biosimilars products comprise PEG-filgrastim, teriparatide, somatropin, filgra …
  • Bionomics Ltd (BNO)-製薬・医療分野:企業M&A・提携分析
    Summary Bionomics Ltd (Bionomics) is a biopharmaceutical company that focuses on the development of treatments for cancer, and central nervous system disorders such as anxiety, depression and Alzheimer's disease. Its pipeline products include BNC210, BNC 105, BNC101, and BNC375. The company uses var …
  • Associated Petroleum Products Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Associated Petroleum Products Inc (APP), a subsidiary of World Fuel Services Corp is an oil and gas company that offers petroleum products. The company provides products such as commercial fuel, aviation fuel, fuels, heating oil, lube oil, fuel additives, propane, marine lubricants and equip …
  • Masraf Al Rayan (Q.S.C.):企業の戦略・SWOT・財務情報
    Masraf Al Rayan (Q.S.C.) - Strategy, SWOT and Corporate Finance Report Summary Masraf Al Rayan (Q.S.C.) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • New Zealand Pharmaceuticals Ltd:企業の戦略的SWOT分析
    New Zealand Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Arab Orient Insurance Company:企業の戦略・SWOT・財務情報
    Arab Orient Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Arab Orient Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • UNeMed Corp:医療機器:M&Aディール及び事業提携情報
    Summary Unemed Corp (Unemed), a subsidiary of University of Nebraska Medical Center, is a healthcare service provider. The company offers services such as inventions, material transfer, confidentiality, intellectual property, startup formation and licensing process. Its technologies include therapeu …
  • Anavex Life Sciences Corp (AVXL):企業の財務・戦略的SWOT分析
    Anavex Life Sciences Corp (AVXL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Graphic Packaging Holding Company:企業の戦略・SWOT・財務分析
    Graphic Packaging Holding Company - Strategy, SWOT and Corporate Finance Report Summary Graphic Packaging Holding Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Motif Bio Plc (MTFB):製薬・医療:M&Aディール及び事業提携情報
    Summary Motif Bio Plc (Motif Bio), formerly Motif Bio Ltd, is a clinical-stage biopharmaceutical company that focuses on the development of novel antibiotics to treat patients with infections caused by multi-drug resistant bacteria. The company develops Iclaprim, a targeted Gram-positive1 antibiotic …
  • Emirates Telecommunications Group Company PJSC:企業のM&A・事業提携・投資動向
    Emirates Telecommunications Group Company PJSC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Emirates Telecommunications Group Company PJSC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business descriptio …
  • Link Healthcare Pty Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Link Healthcare Pty Ltd (LINK), a subsidiary of Clinigen Group Plc, is a healthcare solution provider that provides generic products. The company offers therapeutic products, prescription, OTC medicines and medical devices in various therapeutic areas. It offers products such as relistor, an …
  • Bioxyne Ltd (BXN):企業の財務・戦略的SWOT分析
    Bioxyne Ltd (BXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • McRae Industries, Inc.:戦略・SWOT・企業財務分析
    McRae Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary McRae Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Diana S.A.S.:戦略・SWOT・企業財務分析
    Diana S.A.S. - Strategy, SWOT and Corporate Finance Report Summary Diana S.A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Aradigm Corp (ARDM):医療機器:M&Aディール及び事業提携情報
    Summary Aradigm Corp (Aradigm) is a specialty pharmaceutical company that develops and commercializes inhalation drugs for the prevention and treatment of severe respiratory diseases. The company's product pipeline includes Pulmaquin (ARD-3150) and Lipoquin (ARD-3100) for the treatment of non-cystic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆